The authors reply

New England Journal of Medicine

Volumn 372, Issue 13, 2015, Pages 1274-

  Hornung, Thorsten ^a   Wolf, Dominik ^a   Wenzel, Joerg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; JANUS KINASE 2; JANUS KINASE INHIBITOR; RUXOLITINIB; ANTIINFLAMMATORY AGENT; JANUS KINASE; PYRAZOLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG EFFECT; GENE MUTATION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LETTER; MYELOFIBROSIS; NEOPLASM; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; FEMALE;

ANTI-INFLAMMATORY AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; JANUS KINASES; PYRAZOLES;

EID: 84926115996     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1500688     Document Type: Letter

References (5)

1. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with anti-transcriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 2015;72:449-55.
2. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014;123:2157-60.
3. Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 2011;131:1838-44.
4. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014;123:3832-42.
5. Wenzel J, Tüting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis." J Invest Dermatol 2008;128:2392-402.